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Oxytocin, a hormone involved in numerous physiologic processes, plays a central role in the mechanisms of parturition and
lactation. It acts through its receptor, which belongs to the G-protein-coupled receptor superfamily, while Gq/phospholipase
C (PLC)/inositol 1,4,5-triphosphate (InsP3) is the main pathway via which it exerts its action in the myometrium. Changes
in receptor levels, receptor desensitization, and locally produced oxytocin are factors that inﬂuence the eﬀect of oxytocin on
uterine contractility in labor. Activation of oxytocin receptor causes myometrial contractions by increasing intracellular Ca+2
and production of prostaglandins. Since oxytocin induces contractions, the inhibition of its action has been a target in the
management of preterm labor. Atosiban is today the only oxytocin receptor antagonist that is available as a tocolytic. However, the
quest for oxytocin receptor antagonists with a better pharmacological proﬁle has led to the synthesis of peptide and nonpeptide
molecules such as barusiban, retosiban, L-368,899, and SSR-126768A. Many of these oxytocin receptor antagonists are used only
as pharmacological tools, while others have tocolytic action. In this paper, we summarize the action of oxytocin and its receptor
and we present an overview of the clinical and experimental data of oxytocin antagonists and their tocolytic action.
1.Introduction
Oxytocin (OT) is a nonapeptide synthesized by the magno-
cellular neurons located in the supraoptic and paraventricu-
larnucleiofthehypothalamusandsecretedtothecirculation
by the posterior pituitary and nerve terminals in response
to various stimuli. The sequence of amino acids in the
OT molecule is Cysteine-Tyrosine-Isoleucine-Glutamine-
Asparagine-Cysteine-Proline-Leucine-Glycinamide, with a
sulfur bridge between the two cysteines. OT and vasopressin
have similar structures and diﬀer only in two amino acids.
Oxytocin is also synthesized in many peripheral tissues, for
example,uterus,placenta,amnion,corpusluteum,testis,and
heart [1].
Oxytocin exerts a variety of actions and is involved in
a large number of physiological and pathological processes.
These actions include the regulation of the hypothalamo-
pituitary-adrenal axis in response to stress, pregnancy, luteal
function, maternal behavior, cell proliferation, modulation
of emotional relationships and sexual behavior, erectile
function and ejaculation, antinociception, cardiovascular
function, osteoporosis, and neuropsychiatric disorders [2–
6]. However, its best-known and most well-established roles
are stimulation of uterine contractions during parturition
and milk release during lactation. In 1906, Sir Henry Dale
found that an extract from the human posterior pituitary
gland had a uterotonic eﬀect, and Vincent du Vigneaud et
al. achieved synthesis of oxytocin in 1953 [7]. Since oxytocin
contributes to myometrial contractility, its receptor has been
a target for tocolytic agents. While atosiban is an oxytocin
receptor (OTR) antagonist used for the management of
preterm labor [8], research is ongoing for the tocolytic pro-
perties of various other OTR antagonists.2 International Journal of Endocrinology
2.TheOxytocinReceptor
The oxytocin receptor belongs to the rhodopsin-type class
I G-protein-coupled receptor (GPCR) superfamily. The
gene of the OTR contains 3 introns and 4 exons and is
located in a single copy on chromosome 3p25. Apart from
oxytocin,othermoleculessuchasargininevasopressin(AVP)
and oxytocin agonists or antagonists are able, because of
their similar structure, to bind to the receptor. Binding of
OT to the cell surface transmembrane OTR activates the
receptor which subsequently activates various intracellular
signal pathways, this triggering the numerous eﬀects of
the hormone, including contraction (Figure 1). OTR is
coupled to the Gq/11 a-class guanosine triphosphate (GTP)
binding proteins. The Gq/phospholipase C (PLC)/inositol
1,4,5-triphosphate (InsP3) pathway is the major pathway
mediating the signal of OTR after binding of OT to its recep-
tor. Binding of OT activates, through Gαq/11,P L C ,w h i c h
hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to
InsP3 and diacylglycerol (DAG) [9]. InsP3 releases Ca2+
ions from intracellular stores, while DAG activates protein
kinases type C (PKC), which further phosphorylates other
proteins. Ca2+ ions bind to calmodulin, and the Ca2+-
calmodulin complex activates the myosin light-chain kinase,
thereby causing myometrial muscle contraction. The same
mechanism additionally causes contraction of mammary
myoepithelial cells and milk ejection [1]. However, OTR is
also coupled with other G-proteins, Gs and Gi, which result
in various cellular eﬀects, among them the inhibition of cell
growth [10].
OTR also acts on voltage-gated or receptor coupled
channels, leading to membrane depolarization and the entry
of extracellular Ca2+ to the cells, this further promoting
smooth muscle contractility [11].
Moreover, OTR activates the mitogen-activated pro-
tein kinase (MAPK) and the Rho kinase pathways. Rho-
associated protein kinases are implicated in many cellular
phenomena, including cell contractility, cell migration, and
cell cycle control [12]. Activations of OTR and MAPK
both result in increased cytosolic phospholipase A2 (cPLA2)
activity. cPLA2 hydrolyzes phospholipids and liberates
arachidonic acid, which results in increased production of
prostaglandins via cyclooxygenase-2 (COX-2), an enzyme
that is upregulated by MAPK [13, 14]. The increased pro-
duction of prostaglandins in conjunction with the increase
in intracellular Ca2+ and the activation of the Rho and MAP
kinase pathways results in the contractile eﬀects of OT-OTR
activation.
3. The Oxytocin-OxytocinReceptor inLabor
The mechanism of transition from myometrial quiescence
to labor initiation is a complex one in which numerous
diverse factors contribute in conjunction to the process.
Hormones such as progesterone and CRH have a crucial role
in this transition [15–17]. Immune responses, triggered via
release of cytokines and other mediators of inﬂammation,
are also important, especially in cases of preterm labor [18–
22]. Oxytocin additionally contributes to the mechanism
of labor and interacts with many of the other contributing
factors. However, circulating oxytocin does not seem to be
necessary for the initiation and completion of parturition
in humans, since normal labor can be achieved in the
absence of oxytocin, as in cases of pituitary dysfunction [23].
Furthermore, in humans oxytocin circulation levels do not
increase signiﬁcantly during pregnancy or the beginning of
labor. However, some changes in circulating oxytocin occur
as its levels are increased at the expulsive stage and pulsatile
changes occur in pregnant women at term. As mentioned
above, the oxytocin locally produced in the placenta is likely
to be more important than circulating oxytocin for the
mechanism of labor. Changes to the OTR also occur towards
labor. OTR is upregulated at the end of gestation and in
both term and preterm labor, and sensitivity to oxytocin-
induced contractions is greatly increased [24–26]. Though
it is assumed that steroid hormones may also inﬂuence the
number of OTRs, the mechanisms of regulation are complex
and not as yet fully understood [27–31]. It is of interest that
in rabbits, myometrium under progesterone dominance is
refractory to oxytocin [15].
Coordinated synchronous myometrial contractions dur-
ing labor are achieved through the formation of gap
junctions among cells, which are created by multimers of the
p r o t e i nc o n n e x i n4 3[ 32, 33]. Oxytocin increases connexin-
43 levels and upregulates morphologic gap junctions [34,
35]. After parturition, OTR expression in the mammary
glands remains high thus facilitating lactation, while OT-
binding sites in the uterus decline rapidly [36, 37].
Continuous exposure to high doses of oxytocin leads
to desensitization of the receptor [38]. Desensitization is
a phenomenon that is observed in GPCR receptors and
occurs via diﬀerent mechanisms such as phosphorylation,
internalization, or changes at the receptor mRNA levels.
Desensitization, whose purpose is to protect cells from
overstimulation after prolonged agonist stimulation, can
occur very rapidly, within seconds or minutes, and takes
placein twosteps. Theﬁrststepis thephosphorylation of the
receptor that inhibits G-protein activation, and the second
step is the binding of proteins called arrestins, which prevent
G-protein activation and promote receptor internalization.
Evidence appears to indicate that receptors recycle back to
the cell surface after internalization [39].
OTR desensitization is a phenomenon that occurs after
prolonged agonist stimulation and may last for hours or
even days [36]. The mRNA of the OTR is also reduced after
continuous OT treatment. In cultured human myometrial
cells, treatment with OT for up to 20 hours causes OTR
desensitization and great reduction of OT-binding sites
without receptor internalization. OTR mRNA levels are
reduced, though not the total amount of OTR protein [40].
In vivo, when oxytocin is used to augment labor in pregnant
women, there is also a reduction in myometrial oxytocin
binding sites and in OTR mRNA levels [41]. Oxytocin
receptor downregulation has great clinical signiﬁcance, as
prolonged oxytocin infusion may fail to augment labor or
can lead to postpartum uterine atony that cannot be man-
agedwithadditionaloxytocininfusion.However,asoxytocin
is normally secreted in pulses, this pulsatile secretion mayInternational Journal of Endocrinology 3
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Figure 1: Oxytocin receptor linked signaling pathways resulting in myometrial contraction. Binding of OT to OTR activates Gαq/11 and
then PLC, which hydrolyses PIP2 to InsP3 and DAG. InsP3 causes release of Ca2+ from the sarcoplasmic reticulum, while DAG activates
PKC. Gαq/11 also causes activation of voltage-regulated Ca2+ channels and Ca2+ entry into the cells. Ca2+ binds to calmodulin, and the Ca2+-
calmodulin complex activates MLC kinase, resulting in myometrial contraction. Both OTR and PKC activate the MAPK cascade, while OTR
and MAPK result in increased cPLA2 activity. Increased cPLA2 activity and MAPK activation result in prostaglandin production, which
also contributes to the contractile eﬀect. The activation of the RhoA-ROK cascade by the OTR is another pathway that results in increased
MLC phosphorylation and myometrial contraction. OT: oxytocin, OTR: oxytocin receptor, PLC: phospholipase, PIP2: phosphatidylinositol
4,5-bisphosphate, InsP3: inositol 1,4,5- triphosphate, DAG: diacylglycerol, PKC: protein kinases type C, MLC: myosin light-chain, MAPK:
mitogen-activated protein kinase, cPLA2: cytosolic phospholipase A2, ROK: RhoA associated protein kinase.
prevent desensitization from occurring. This might explain
why lower doses of oxytocin are required to augment labor
when it is administered in pulses and higher doses when it is
infused continuously [42].
4. OxytocinAgonists
OTR agonist molecules have been developed and studied as
pharmacological tools or as potential drugs for the manage-
ment of neuropsychiatric diseases including anxiety-related
disorders, schizophrenia, and autism. OTR agonists may
be peptides ([Thr4]OT, [HO1][Thr4]OT, [Thr4,Gly7]OT,
[HO1][Thr4,Gly7]OT and other molecules) or nonpeptides
(WAY-267464 and other compounds) [43–45]. WAY-267464
exertsoxytocinergicactions,suchasanxiolyticeﬀectsinmice
[46].
Synthetic oxytocin is used to augment labor and treat
postpartum hemorrhage. Demoxytocin is an oxytocin ana-
logue that has been used for labor induction, though it
h a sb e e np r o v e nl e s se ﬀective compared to prostaglandins
[47]. Carbetocin is a peptide synthetic oxytocin analogue
indicated for the prevention of uterine atony after cesarean
section with spinal or epidural anesthesia: it has a longer
half-life than oxytocin and possesses the advantage that
it is administered in a single dose, intramuscularly or
intravenously [48].
5. OxytocinAntagonistsas Tocolytic Agents
The therapeutic target in the treatment of preterm labor
is currently the pharmacological inhibition of uterine con-
tractions with the use of various tocolytic agents. Tocolytic
agents are used to maintain pregnancy for 24–48 hours to
allow corticosteroids administration to act and to permit the
transfer of the mother to a center with a neonatal intensive
care unit. Ritodrine (a beta-receptor agonist), nitric oxide
donors(asglyceryltrinitrate),calcium-channelblockers,and
COX-2 inhibitors such as indomethacin are some of the
currently available tocolytics [8].
5.1. Peptide OTR Antagonists. Selective human oxytocin
receptors antagonists have also been synthesized as tocolytic
agents for the management of preterm labor. Atosiban is an
oxytocinanalogue(1-Deamino-2-D-Tyr-(O-ethyl)-4-Thr-8-
ornoxytocin) based on modiﬁcation of some amino acids
in the structure of oxytocin at positions 1, 2, 4, and 84 International Journal of Endocrinology
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Figure 2: The structure of oxytocin, arginine vasopressin, and atosiban.
(Figure 2). It is a mixed vasopressin (V1a) and oxytocin
receptor antagonist that blocks OT binding to OTR and is
the only oxytocin antagonist used today for the treatment
of preterm labor in Europe and other countries, though
not in the USA. However, as it is also an antagonist of
the vasopressin receptor V1a, this results in related unde-
sirable eﬀects. The onset of uterine relaxation after atosiban
administration is rapid. Atosiban is given intravenously for
up to 48 hours. Clinically, atosiban is as eﬀective as β2-
adrenergic agonists and with lesser adverse eﬀects. When
subcutaneously administered as maintenance therapy after
a period of preterm labor, atosiban failed to reduce the
incidence of preterm birth or improve neonatal outcome
[49].
Clinically, atosiban is safer than beta-receptor ago-
nists. Atosiban is comparable in clinical eﬀectiveness to
conventional beta-agonist therapy (ritodrine, salbutamol,
or terbutaline), but it is associated with fewer maternal
cardiovascular side eﬀects and is better tolerated [50–53].
Compared to calcium channel blockers, atosiban has been
shownequallyeﬀectiveasnifedipineandwithfewermaternal
side eﬀects [54, 55]. Cyclooxygenase inhibitors also present
signiﬁcant side eﬀects [56]. Conversely, there is at present
insuﬃcient evidence to recommend the use of nitric oxide
donors as inhibitors of preterm delivery [57]. However,
atosiban has not been proven to be superior in terms of
neonatal outcome, as concerns have been described in some
studies [58].
Unfortunately, atosiban displays some disadvantages
when used as a tocolytic. It has limited bioavailability and
requires parenteral administration and hospitalization, has
low aﬃnity of the OTR, and is also an antagonist for the V1a
receptors that cause side eﬀects. These limitations have led to
eﬀorts for the discovery of new peptide and nonpeptide OT
antagonists for the management of preterm labor. Most of
these substances are still being evaluated at an experimental
level (Table 1), and clinical studies in most cases have not
been successfully completed [43].
A number of highly selective OT peptidic antagonists
havebeendesignedandsynthesized,liked(CH2)5[Tyr(Me)2]·
OVT, desGly-NH2,d(CH2)5[Tyr(Me)2,Thr4]OVT, desGly-
NH2,d ( C H 2)5[D-Tyr2,Thr4]OVT, d(CH2)5,[D-Thi2,Thr4,
Tyr-NH2
9]OVT, and desGly-NH2,d(CH2)5[D-Trp2,Thr4,
Dap5]OVT.ThesemoleculesarebothOTRandAVPreceptor
antagonists but are more potent as OT antagonists than as
V1a antagonists. However, experiments have revealed strik-
ing diﬀerences between species concerning the aﬃnity of
many antagonists to the various receptors [59].
Some of the new peptide OT/AVP antagonists have
higher aﬃnity for human receptor than the peptide ato-
siban. These new peptides are desGly-NH2,d(CH2)5[D-
2-Nal2,Thr4]OVT, desGly-NH2,d(CH2)5[2-Nal2,Thr4]OVT,
d(CH2)5[D-2-Nal2,Thr4,Tyr-NH2
9]OVT, and d(CH2)5[2-
Nal2,Thr4,Tyr-NH2
9]OVT and may be candidates as poten-
tial tocolytic agents [43].
Barusiban is a selective peptide oxytocin antagonist with
ah i g ha ﬃnity for the human OTR and low for the V1a
receptor. It has a higher potency and a longer duration
of action than atosiban. In contractility studies with iso-
lated human myometrium, barusiban inhibits oxytocin-
induced myometrial contractions of both preterm and term
myometrium, and this action was at least as potent as the
action of atosiban [60]. In nonhuman primates, barusiban
also inhibits oxytocin-induced myometrial contractions [61,
62]. In pregnant monkeys, in which atosiban and barusiban
were tested following induction of contractions by OT,
the duration of action of barusiban was generally longer
than that of atosiban (13–15 hours compared to 1.5–
3 hours). For long-term treatment, continuous high-dose
infusions of barusiban or the beta-2 agonist fenoterol were
administered: barusiban moderated intrauterine pressure
increase in response to daily OT challenge and prolonged
pregnancy more eﬀectively than fenoterol [63].
However,despitethepromisingresultsinnonhumanpri-
mates, in a recent study in pregnant women, barusiban was
not more eﬀective than placebo in stopping preterm labor.
In a multicenter trial that was conducted at 21 participating
centers in 6 diﬀerent European countries, participants were
randomly assigned to receive a single intravenous bolus dose
of placebo or barusiban. There was no signiﬁcant diﬀerenceInternational Journal of Endocrinology 5
Table 1: The most extensively studied OT antagonists and their experimental or clinical applications.
Oxytocin antagonists Organism Experimental or therapeutic application
(I) Peptide
1-Deamino-2-D-Tyr-(O-ethyl)-4-Thr-8-
ornoxytocin
(Atosiban)
Human Clinically used tocolytic agent
d(CH2)5[Tyr(Me)2]OVT Animals/human cells and tissues, or both Pharmacological tool in experimental
studies of OT functions
desGly–NH2,d(CH2)5[Tyr(Me)2,Thr4]OVT Animals/human cells and tissues, or both Pharmacological tool in experimental
studies of OT functions
desGly–NH2,d(CH2)5[D-Tyr2,Thr4]OVT Animals/human cells and tissues, or both Pharmacological tool in experimental
studies of OT functions
d(CH2)5,[D-Thi2,Thr4,Tyr–NH9
2]OVT Animals/human cells and tissues, or both Pharmacological tool in experimental
studies of OT functions
desGly–NH2,d(CH2)5[D-Trp2,Thr4,Dap5]OVT Animals/human cells and tissues, or both Pharmacological tool in experimental
studies of OT functions
desGly–NH2,d(CH2)5[D-2-Nal2,Thr4]OVT Animals/human cells and tissues, or both Pharmacological tool in experimental
studies of OT functions
desGly–NH2,d(CH2)5[2-Nal2,Thr4]OVT Animals/human cells and tissues, or both Pharmacological tool in experimental
studies of OT functions
d(CH2)5[D-2-Nal2,Thr4,Tyr–NH9
2]OVT Animals/human cells and tissues, or both Pharmacological tool in experimental
studies of OT functions
d(CH2)5[2-Nal2,Thr4,Tyr–NH9
2]OVT Animals/human cells and tissues, or both Pharmacological tool in experimental
studies of OT functions
FE 200 400 (Barusiban) Monkeys/human myometrial tissue Pharmacological tool in experimental
studies of OT functions
(II) Nonpeptide
GSK221149A (Retosiban) Rats
Tocolytic action. A phase ll clinical trial for
its use as a tocolytic in humans has not yet
been completed
L-368,899 Animals/human cells and tissues, or both
Pharmacological tools in experimental
studies of OT function. CNS eﬀects. Inhibits
spontaneous nocturnal uterine contractions
in pregnant rhesus monkeys. Clinical
studies discontinued
L-371,257 Animals/human cells and tissues, or both Pharmacological tool in experimental
studies of OT functions
WAY-162720 Animals/human cells and tissues, or both Pharmacological tool in experimental
studies of OT functions
SSR-126768A Rats/human myometrial tissue
Tocolytic action in rats. Inhibits the
response to OT in term human pregnant
uterine sections
between the placebo group and any of the barusiban groups
with regard to the percentage of women who did not deliver
within 48 hours, nor was there any signiﬁcant decrease in
the number of uterine contractions between the barusiban
groups and placebo group. Additionally, there were no
statistical diﬀerences in maternal or neonatal adverse eﬀects
between placebo and barusiban groups [64].
5.2. Nonpeptide OTR Antagonists. Since peptide antago-
nists lack oral bioavailability, pharmaceutical companies
have searched for an eﬀective nonpeptide oxytocin antago-
nist. GSK221149A (2 -methyl-1 ,3 -oxazol-4 -yl morpholine
amide derivative 74), known as retosiban, is such a nonpep-
tide oxytocin antagonist. In vitro experiments using Chinese
hamsterovary(CHO)cellmembranesexpressinghumanOT
receptors or human vasopressin (V1a, V1b, V2) receptors
and human endothelial kidney (HEK) cells expressing rat
oxytocin receptors revealed that retosiban has a higher aﬃn-
ityforhumanandratoxytocinreceptorsthanforV1aandV2
receptors. In rats, when administered orally or intravenously,
retosiban produced a dose-dependent decrease in oxytocin-
induced uterine contraction. This eﬀect was observed after
either single or multiple dosing for 4 days. Also, spontaneous
uterine contractions in late-term pregnant rats (at 19–21
days gestation) were signiﬁcantly reduced by intravenous
administration of retosiban [65]. Retosiban is more than6 International Journal of Endocrinology
15-fold more potent compared to atosiban for the OTR
[66]: it is at present on a Phase ll Clinical trial investigating
its action as a tocolytic, but the results have not as yet been
published [67].
Anothernonpeptide oxytocinantagonistisL-368,899(1-
(((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl) bu-
tyramido) bicyclo [2.2.1]-heptan-1(S)-yl)methyl) sulfonyl)-
4(2methylphenyl) piperazine). In pregnant rhesus monkeys,
L-368,899 was shown to be a potent OT antagonist that
inhibits spontaneous nocturnal uterine contractions. In
women, L-368,899 also blocked OT-stimulated uterine
activity postpartum with a potency similar to that observed
in the pregnant rhesus monkey [68]. However, no further
clinical evaluation was undertaken because of suboptimal
oral bioavailability and pharmacokinetics [69]. L-368,899 is
also brain penetrant, and experiments in one adult female
monkey demonstrated that it altered maternal and sexual
behavior [4].
SSR-126768A(4-Chloro-3-[(3R)-(+)-5-chloro-1-(2,4-di-
methoxybenzyl)-3-methyl-2-oxo-2,3-dihydro-1H-indol-3-
yl]-N-ethyl-N-(3-pyridylmethyl)-benzamide, Hydrochlo-
ride), a nonpeptide oxytocin antagonist, produced a com-
petitive antagonistic eﬀect against OT in rat myometrial
strips, as in conscious rat after oral administration. After
oral administration in pregnant rats in labor, SSR-126768A
signiﬁcantly delayed parturition, similarly to ritodrine,
and had a rapid onset of action, and its duration was
still observed 24 hours after treatment. Experimentally,
SSR-126768A inhibited the response to OT at-term human
pregnant uterus sections, this eﬀect being observed in a
concentration-dependent manner [70].
As nonpeptide OTR antagonists display high selectivity
for the OTR receptor, they may provide orally administered
tocolytics for both the acute and long-term management of
preterm labor, which would undoubtedly oﬀer a signiﬁcant
improvement in neonatal outcomes.
Inwomenwhogointopretermlabor,relcovaptan(which
is a nonpeptide vasopressin V1a receptor antagonist) was
reported to inhibit uterine contractions [71, 72]. In a study
in 18 women in preterm labor between 32–36 weeks, 12
patients received at random a single oral dose of relcovaptan
and 6 patients received placebo, while uterine contractions,
were monitored up to 6h after administration. Relcovaptan
inhibited uterine contractions, and, compared with placebo,
the diﬀerence was statistically signiﬁcant. Relcovaptan has
also revealed positive initial results in tests against Raynaud’s
disease, dysmenorrhoea, and experimentally in ischemic
brain damage, although it has not yet been approved for
clinical use [73–76].
6. Conclusion
Oxytocinisaneuropeptidewhichaﬀectsuterinecontractility
during labor. Its receptor is a transmembrane receptor
belonging to the G-protein-coupled receptor superfamily.
The main signaling pathway is the Gq/LPC/Ins3 pathway,
but the MAPK and the RhoA/Rho kinase pathways are also
activated, contributing to increased prostaglandin produc-
tionanddirectcontractileeﬀectonmyometrialcells.Various
peptide and nonpeptide antagonists have been developed as
potential tocolytic agents or research tools for the various
OT functions. Atosiban is currently available for use as a
tocolytic agent. However, other oxytocin antagonists, both
peptide and nonpeptide, such as barusiban, retosiban, L-
368,899, and SSR-126768, have displayed tocolytic action
and are under further investigation. The future use of OTR
antagonists possessing a better pharmacological proﬁle than
atosiban is a promising research ﬁeld that aims to further
improve the management of preterm labor.
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